BACKGROUND: We examined a large cohort of serous tubo-ovarian tumors with 26 immunohistochemical markers, with the aim to assess their value for differential diagnosis and prognosis. METHODS: Immunohistochemical analyses with 26 immunomarkers were performed on 250 primary tubo-ovarian tumors including 114 high grade serous carcinomas (HGSC), 97 low grade serous carcinomas (LGSC), and 39 serous borderline tumors (micropapillary variant, mSBT). The associations of overall positivity with clinicopathological characteristics were evaluated using the chi-squared test or Fisher's Exact test. RESULTS: We found significantly different expression of p53, p16, ER, PR, PTEN, PAX2, Mammaglobin, RB1, Cyclin E1, stathmin, LMP2, L1CAM, CD44, and Ki67 in HGSCs compared to LGSCs. No significant differences were found between LGSC and mSBT. None of the other included markers (PAX8, ARID1A, HNF1B, Napsin A, CDX2, SATB2, MUC4, BRG1, AMACR, TTF1, BCOR, NTRK) showed any differences between the investigated serous tumors. Regarding the prognosis, only PR and stathmin showed a statistically significant prognostic meaning in LGSCs, with better overall survival (OS) and recurrence-free survival (RFS) in cases positive for PR, and worse outcome (RFS) for stathmin. None of the study markers showed prognostic significance in HGSCs. CONCLUSION: We provided an extensive immunohistochemical analysis of serous ovarian/tubo-ovarian tumors. Although we found some differences in the expression of some markers in HGSCs compared to LGSCs, only p53, p16, and Ki67 seem to be useful in real diagnostic practice. We also suggested the best discriminative cut-off for Ki67 (10% of positive tumor cells) for distinguishing HGSC from LGSC. We found prognostic significance of PR and stathmin in LGSCs. Moreover, the high expression of stathmin could also be of predictive value in ovarian carcinomas as target-specific anti-stathmin effectors are potential therapeutic targets.

Department of Oncological Pathology Masaryk Memorial Cancer Institute Brno Czech Republic

Department of Pathology and Molecular Medicine 2nd Faculty of Medicine Charles University and Motol University Hospital Prague Czech Republic

Department of Pathology and Molecular Medicine 3rd Faculty of Medicine Charles University Thomayer University Hospital Prague Czech Republic

Department of Pathology Charles University 3rd Faculty of Medicine University Hospital Královské Vinohrady 10034 Prague Czech Republic

Department of Pathology Faculty of Medicine University of Debrecen 4032 Debrecen Hungary

Department of Pathology University Hospital Brno and Medical Faculty Masaryk University Brno Czech Republic

Institute of Pathology 1st Faculty of Medicine Charles University and General University Hospital Prague 12800 Prague Czech Republic

The Fingerland Department of Pathology Charles University Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové Hradec Králové Czech Republic

Zobrazit více v PubMed

Seidman JD, Ronnett BM, Shih lM, Kathleen R. Cho, Kurman RJ. Epithelial Tumors of the Ovary. In: Kurman RJ, Ellenson LH, Ronnett BM, editors. Blaustein's pathology of the female genital tract. New York: Springer Berlin Heidelberg; 2019. p. 841-966.

McCluggage WG, Lax SF, Longrace TA, Malpica A, Soslow RA. Tumours of the ovary. In: Cheung AN, Ellenson LH, Gilks CB, Kim K-R, Kong CS, Lax SF, Longrace TA, Malpica A, McCluggage WG, Oliva E, Rabban JT, Soslow RA, editors. WHO Classification of Tumours Editorial Board. Female genital tumours. 5th edition. Lyon: International Agency for Research on Cancer; 2020. p. 31-163.

Bell DA, Longacre TA, Prat J, Kohn EC, Soslow RA, Ellenson LH, et al. Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives. Hum Pathol. 2004;35(8):934–948. doi: 10.1016/j.humpath.2004.03.005. PubMed DOI

Gershenson DM, Sun CC, Lu KH, Coleman RL, Sood AK, Malpica A, et al. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol. 2006;108(2):361–368. doi: 10.1097/01.AOG.0000227787.24587.d1. PubMed DOI

Singh N, McCluggage WG, Gilks CB. High-grade serous carcinoma of tubo-ovarian origin: recent developments. Histopathol. 2017;71(3):339–356. doi: 10.1111/his.13248. PubMed DOI

Kurman RJ. Origin and molecular pathogenesis of ovarian high-grade serous carcinoma. Ann Oncol. 2013;24(Suppl 10):x16–21. doi: 10.1093/annonc/mdt463. PubMed DOI

Ferguson DC, Long DJ, Smith MC, Craig-Owens LD, Means J, Fadare O, et al. Comparative analysis of Rb1, P16 and ER as diagnostic, prognostic and potential targets for therapeutic agents in ovarian epithelial tumors: an immunohistochemical study of 130 ovarian carcinomas. J Ovarian Res. 2015;8:34. doi: 10.1186/s13048-015-0163-1. PubMed DOI PMC

Hagemann IS, Pfeifer JD, Cao D. Mammaglobin expression in gynecologic adenocarcinomas. Hum Pathol. 2013;44(4):628–635. doi: 10.1016/j.humpath.2012.07.013. PubMed DOI

Karst AM, Levanon K, Duraisamy S, Liu JF, Hirsch MS, Hecht JL, et al. Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas. Gynecol Oncol. 2011;123(1):5–12. doi: 10.1016/j.ygyno.2011.05.021. PubMed DOI PMC

Köbel M, Piskorz AM, Lee S, Lui S, LePage C, Marass F, et al. Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma. J Pathol Clin Res. 2016;2(4):247–258. doi: 10.1002/cjp2.53. PubMed DOI PMC

Zhang J, Chang B, Liu J. CD44 standard form expression is correlated with high-grade and advanced-stage ovarian carcinoma but not prognosis. Hum Pathol. 2013;44(9):1882–1889. doi: 10.1016/j.humpath.2013.02.016. PubMed DOI PMC

Dundr P, Bazalova B, Bartu M, Bosse T, Drozenova J, Fabian P, et al. The cytokeratin 17 expression in primary ovarian tumors has diagnostic but not prognostic significance. Virchows Arch. 2022;481(2):201–212. doi: 10.1007/s00428-022-03338-z. PubMed DOI

McCluggage WG, Soslow RA, Gilks CB. Patterns of p53 immunoreactivity in endometrial carcinomas: 'all or nothing' staining is of importance. Histopathol. 2011;59(4):786–788. doi: 10.1111/j.1365-2559.2011.03907.x. PubMed DOI

Kuhn E, Kurman RJ, Sehdev AS, Shih IM. Ki-67 labeling index as an adjunct in the diagnosis of serous tubal intraepithelial carcinoma. Int J Gynecol Pathol. 2012;31(5):416–422. doi: 10.1097/PGP.0b013e31824cbeb4. PubMed DOI PMC

Altman AD, Nelson GS, Ghatage P, McIntyre JB, Capper D, Chu P, et al. The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors. Mod Pathol. 2013;26(9):1255–1263. doi: 10.1038/modpathol.2013.55. PubMed DOI

Sallum LF, Andrade L, Ramalho S, Ferracini AC, de Andrade NR, Brito ABC, et al. WT1, p53 and p16 expression in the diagnosis of low- and high-grade serous ovarian carcinomas and their relation to prognosis. Oncotarget. 2018;9(22):15818–15827. doi: 10.18632/oncotarget.24530. PubMed DOI PMC

Na K, Sung JY, Kim HS. TP53 Mutation Status of Tubo-ovarian and Peritoneal High-grade Serous Carcinoma with a Wild-type p53 Immunostaining Pattern. Anticancer Res. 2017;37(12):6697–6703. PubMed

Cheasley D, Nigam A, Zethoven M, Hunter S, Etemadmoghadam D, Semple T, et al. Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities. J Pathol. 2021;253(1):41–54. doi: 10.1002/path.5545. PubMed DOI

Boyd C, McCluggage WG. Low-grade ovarian serous neoplasms (low-grade serous carcinoma and serous borderline tumor) associated with high-grade serous carcinoma or undifferentiated carcinoma: report of a series of cases of an unusual phenomenon. Am J Surg Pathol. 2012;36(3):368–375. doi: 10.1097/PAS.0b013e31823732a9. PubMed DOI

Chui MH, Momeni Boroujeni A, Mandelker D, Ladanyi M, Soslow RA. Characterization of TP53-wildtype tubo-ovarian high-grade serous carcinomas: rare exceptions to the binary classification of ovarian serous carcinoma. Mod Pathol. 2021;34(2):490–501. doi: 10.1038/s41379-020-00648-y. PubMed DOI PMC

Zarei S, Wang Y, Jenkins SM, Voss JS, Kerr SE, Bell DA. Clinicopathologic, Immunohistochemical, and Molecular Characteristics of Ovarian Serous Carcinoma With Mixed Morphologic Features of High-grade and Low-grade Serous Carcinoma. Am J Surg Pathol. 2020;44(3):316–328. doi: 10.1097/PAS.0000000000001419. PubMed DOI

Milea A, George SH, Matevski D, Jiang H, Madunic M, Berman HK, et al. Retinoblastoma pathway deregulatory mechanisms determine clinical outcome in high-grade serous ovarian carcinoma. Mod Pathol. 2014;27(7):991–1001. doi: 10.1038/modpathol.2013.218. PubMed DOI

Rambau PF, Vierkant RA, Intermaggio MP, Kelemen LE, Goodman MT, Herpel E, et al. Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. J Pathol Clin Res. 2018;4(4):250–261. doi: 10.1002/cjp2.109. PubMed DOI PMC

Chen M, Yao S, Cao Q, Xia M, Liu J, He M. The prognostic value of Ki67 in ovarian high-grade serous carcinoma: an 11-year cohort study of Chinese patients. Oncotarget. 2017;8(64):107877–107885. doi: 10.18632/oncotarget.14112. PubMed DOI PMC

Köbel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med. 2008;5(12):e232. doi: 10.1371/journal.pmed.0050232. PubMed DOI PMC

Mahadevappa A, Krishna SM, Vimala MG. Diagnostic and Prognostic Significance of Ki-67 Immunohistochemical Expression in Surface Epithelial Ovarian Carcinoma. J Clin Diagn Res. 2017;11(2):Ec08–ec12. PubMed PMC

Mishra SK, Crasta JA. An immunohistochemical comparison of P53 and Bcl-2 as apoptotic and MIB1 as proliferative markers in low-grade and high-grade ovarian serous carcinomas. Int J Gynecol Cancer. 2010;20(4):537–541. doi: 10.1111/IGC.0b013e3181d6de3f. PubMed DOI

Sehouli J, Braicu EI, Richter R, Denkert C, Jank P, Jurmeister PS, et al. Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the Tumor Bank Ovarian Cancer Network. Hum Pathol. 2019;85:299–308. doi: 10.1016/j.humpath.2018.10.020. PubMed DOI

Høgdall EV, Christensen L, Høgdall CK, Blaakaer J, Gayther S, Jacobs IJ, et al. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study. Oncol Rep. 2007;18(5):1051–1059. PubMed

Lee P, Rosen DG, Zhu C, Silva EG, Liu J. Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. Gynecol Oncol. 2005;96(3):671–677. doi: 10.1016/j.ygyno.2004.11.010. PubMed DOI

Sieh W, Köbel M, Longacre TA, Bowtell DD, deFazio A, Goodman MT, et al. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol. 2013;14(9):853–862. doi: 10.1016/S1470-2045(13)70253-5. PubMed DOI PMC

Matsuo K, Sheridan TB, Mabuchi S, Yoshino K, Hasegawa K, Studeman KD, et al. Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma. Gynecol Oncol. 2014;133(3):473–479. doi: 10.1016/j.ygyno.2014.03.563. PubMed DOI PMC

Chen S, Dai X, Gao Y, Shen F, Ding J, Chen Q. The positivity of estrogen receptor and progesterone receptor may not be associated with metastasis and recurrence in epithelial ovarian cancer. Sci Rep. 2017;7(1):16922. doi: 10.1038/s41598-017-17265-6. PubMed DOI PMC

Shen Z, Luo H, Li S, Sheng B, Zhao M, Zhu H, et al. Correlation between estrogen receptor expression and prognosis in epithelial ovarian cancer: a meta-analysis. Oncotarget. 2017;8(37):62400–62413. doi: 10.18632/oncotarget.18253. PubMed DOI PMC

Llaurado Fernandez M, Dawson A, Kim H, Lam N, Russell H, Bruce M, et al. Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma. Gynecol Oncol. 2020;157(1):12–20. doi: 10.1016/j.ygyno.2019.11.029. PubMed DOI

Dundr P, Simon K, Nemejcova K, Bartu M, Ticha I, Michalkova R, et al. Stathmin is a potential therapeutic target but not a prognostic marker in melanoma: an immunohistochemical study of 323 melanocytic lesions. Melanoma Res. 2019;29(2):157–162. doi: 10.1097/CMR.0000000000000550. PubMed DOI

Howitt BE, Nucci MR, Drapkin R, Crum CP, Hirsch MS. Stathmin-1 expression as a complement to p16 helps identify high-grade cervical intraepithelial neoplasia with increased specificity. Am J Surg Pathol. 2013;37(1):89–97. doi: 10.1097/PAS.0b013e3182753f5a. PubMed DOI

Su D, Smith SM, Preti M, Schwartz P, Rutherford TJ, Menato G, et al. Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel. Cancer. 2009;115(11):2453–2463. doi: 10.1002/cncr.24282. PubMed DOI

Wang S, Akhtar J, Wang Z. Anti-STMN1 therapy improves sensitivity to antimicrotubule drugs in esophageal squamous cell carcinoma. Tumour Biol. 2015;36(10):7797–7806. doi: 10.1007/s13277-015-3520-1. PubMed DOI

Watanabe A, Suzuki H, Yokobori T, Tsukagoshi M, Altan B, Kubo N, et al. Stathmin1 regulates p27 expression, proliferation and drug resistance, resulting in poor clinical prognosis in cholangiocarcinoma. Cancer Sci. 2014;105(6):690–696. doi: 10.1111/cas.12417. PubMed DOI PMC

Novak M, Lester J, Karst AM, Parkash V, Hirsch MS, Crum CP, et al. Stathmin 1 and p16(INK4A) are sensitive adjunct biomarkers for serous tubal intraepithelial carcinoma. Gynecol Oncol. 2015;139(1):104–111. doi: 10.1016/j.ygyno.2015.07.100. PubMed DOI PMC

Lv H, Shi Y, Zhang L, Zhang D, Liu G, Yang Z, et al. Polyploid giant cancer cells with budding and the expression of cyclin E, S-phase kinase-associated protein 2, stathmin associated with the grading and metastasis in serous ovarian tumor. BMC Cancer. 2014;14:576. doi: 10.1186/1471-2407-14-576. PubMed DOI PMC

Biaoxue R, Xiguang C, Hua L, Shuanying Y. Stathmin-dependent molecular targeting therapy for malignant tumor: the latest 5 years' discoveries and developments. J Transl Med. 2016;14(1):279. doi: 10.1186/s12967-016-1000-z. PubMed DOI PMC

The role of stathmin expression in the differential diagnosis, prognosis, and potential treatment of ovarian sex cord-stromal tumors

Immunohistochemical expression of PRAME in 485 cases of epithelial tubo-ovarian tumors